论Aβ单抗治疗阿尔茨海默病的临床实践和进展  

Anti-Amyloid-β monoclonal antibodies for alzheimer's disease: clinical practice and progress

作　　者：肖金雯 任汝静[1] 王刚[1] Jinwen XIAO;Rujing REN;Gang WANG(Department of Neurology,Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine,Shanghai,200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院神经内科,上海200025

出　　处：《阿尔茨海默病及相关病杂志》2023年第1期7-11,共5页Chinese Journal of Alzheimer's Disease and Related Disorders

摘　　要：随着Aβ单抗药物研究的不断进展和疾病修饰治疗理念的不断深入,近期Aβ单抗治疗阿尔茨海默病的临床试验及临床研究取得了重要进展,以Aducanumab、Lecanemab(BAN2401)为代表的药物相继获批,在临床上获得试用。2022年12月11日,由作者团队在海南博鳌乐城医疗先行区首次采用Aducanumab单抗治疗轻度阿尔茨海默病的临床用药,从而在国内正式开启了Aβ单抗治疗阿尔茨海默病的序幕。本文拟就Aβ单抗治疗阿尔茨海默病的研究进展和临床实践进行一系统述评。With the development of researches on anti-amyloid-β(Aβ)monoclonal antibodies(mAbs)and the deeper understanding of disease-modifying therapies,related clinical trials and studies on anti-AβmAbs for treating Alzheimer's disease recently have made great progress.Due to successive FDA approval of Aducanumab and Lecanemab(BAN2401),these drugs have been used in clinic.On December 112022,Aducanumab was first applied to the treatment of mild Alzheimer's disease for clinical use by the author’s team in Lecheng medical pioneer area in Boao Hainan,which officially initiating the anti-AβmAbs therapy for Alzheimer's disease in China.This review systematically summarizes the research progress and clinical practice of anti-AβmAbs for the treatment of Alzheimer's disease.

关 键 词：淀粉样蛋白 阿尔茨海默病 疾病修饰治疗 淀粉样蛋白相关成像异常 

分 类 号：R749.16[医药卫生—神经病学与精神病学]